NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Efficacy of Azithromycin for Eradication of Pertussis with an Assessment of Disease Morbidity and Work Productivity.

PICHICHERO ME, CASEY JR, HOEGER WJ; Interscience Conference on Antimicrobial Agents and Chemotherapy (43rd: 2003: Chicago, Ill.).

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2003 Sep 14-17; 43: abstract no. G-458.

University of Rochester, Rochester, NY.

BACKGROUND: Our objectives were to assess the efficacy of a 5-day course of azithromycin in children and their parents with pertussis; and to evaluate disease morbidity and work productivity during illness. METHODS: Children and their parents presenting with a clinically defined pertussis syndrome were eligible for study. Patients received azithromycin 10 mg/kg/day on day 1, then 5 mg/kg/day for the next 4 days for a maximum of 1000 mg on day 1 and 500 mg on day 2-5. Nasopharyngeal (NP) specimens for culture and polymerase chain reaction (PCR) testing and serology for Bordetella pertussis were evaluated at enrollment and at day 2-3 and/or 14-21 after enrollment. Clinical assessments and adverse event solicitation occurred at all visits. RESULTS: 121 subjects were enrolled with clinical pertussis. 29 subjects were culture positive, 5 additional subjects were PCR positive and 55 additional subjects were serology positive for B pertussis infection for a total of 89 laboratory-confirmed cases. The median age of the 121 subjects was 8.5 years; mean = 13 +/- 12 years (range = 6 months to 47 years). Eradication of B pertussis from the NP occurred in 33 (97%) of 34 culture/PCR positive patients by day 2-3 of azithromycin treatment; 100% were culture/PCR negative at the 14-21 day follow-up visit. Adverse events occurred in 14 (12%) subjects (all mild gastrointestinal) and compliance with the medication regimen was high. Median number of days of cough before diagnosis was 9; after starting treatment it took a median of 9 days before subjects reported clinical improvement. The median number of days to full recovery was 32 days; mean = 28 +/- 19 days (range = 5-90 days). 67 adults reported missing work a mean = 3 +/- 2 days; for those who did work productivity was below 100% for 48%. CONCLUSIONS: A 5-day course of azithromycin appears effective for rapid eradication of pertussis. Even so, the prolonged cough of pertussis causes considerable morbidity and loss of work productivity.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Adult
  • Azithromycin
  • Bordetella pertussis
  • Child
  • Cough
  • Humans
  • Morbidity
  • Nasopharynx
  • Pertussis Vaccine
  • Physical Examination
  • Polymerase Chain Reaction
  • Serologic Tests
  • Whooping Cough
  • methods
Other ID:
  • GWAIDS0026346
UI: 102265970

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov